As patients regain control over their health, stress levels tend to decline
Why Brand-Name Cant Match Price Structural Barriers: Public Company Obligations: Must maximize shareholder return Quarterly earnings pressure Executive compensation tied to profits Cant dramatically reduce price without stock impact Sunk Costs: Billions invested in development Need to recoup investment Justify to shareholders and board Complex Distribution System: PBMs demand rebates Wholesalers take cut Pharmacy margins Cant easily change system Market Dynamics: Limited competition (patent protection) Can charge premium prices Demand exceeds supply No pressure to reduce Eli Lilly unlikely to reduce tirzepatide prices significantly while patents protected
Selective disruption of mitochondrial thiol redox state in cells and in vivo
Akuta N, Kawamura Y, Fujiyama S, Sezaki H, Hosaka T, Kobayashi M, et al
Our Tesamorelin-based therapies directly target harmful abdominal fat, support metabolic balance, and restore vitality, all through a personalized, medically guided approach
Originally developed for type 2 diabetes, they are now widely used for weight loss due to their appetite-suppressing effects